HighTower Advisors LLC Acquires New Position in ImmunityBio, Inc. (NASDAQ:IBRX)

HighTower Advisors LLC bought a new position in shares of ImmunityBio, Inc. (NASDAQ:IBRX) during the third quarter, Holdings Channel reports. The fund bought 36,612 shares of the company’s stock, valued at approximately $136,000.

Several other institutional investors and hedge funds also recently bought and sold shares of the company. Captrust Financial Advisors purchased a new stake in shares of ImmunityBio during the 3rd quarter valued at approximately $41,000. Algert Global LLC purchased a new stake in ImmunityBio in the second quarter valued at $86,000. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of ImmunityBio by 22.0% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 25,192 shares of the company’s stock valued at $99,000 after purchasing an additional 4,545 shares during the last quarter. Dimensional Fund Advisors LP purchased a new position in shares of ImmunityBio during the 2nd quarter worth $105,000. Finally, Courier Capital LLC increased its position in shares of ImmunityBio by 50.0% during the 3rd quarter. Courier Capital LLC now owns 30,000 shares of the company’s stock worth $112,000 after purchasing an additional 10,000 shares during the last quarter. 8.58% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research analysts have weighed in on IBRX shares. D. Boral Capital reaffirmed a “buy” rating and set a $30.00 target price on shares of ImmunityBio in a research note on Friday, December 20th. EF Hutton Acquisition Co. I raised shares of ImmunityBio to a “strong-buy” rating in a research report on Wednesday, October 23rd.

ImmunityBio Trading Down 1.5 %

IBRX opened at $2.63 on Thursday. The stock’s 50-day moving average price is $4.43 and its 200 day moving average price is $4.66. ImmunityBio, Inc. has a 12-month low of $2.50 and a 12-month high of $10.53. The firm has a market cap of $1.83 billion, a price-to-earnings ratio of -2.86 and a beta of 0.86.

ImmunityBio Profile

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.